Lärkberget (LARK) Status Update summary
Event summary combining transcript, slides, and related documents.
Status Update summary
15 Oct, 2026Webinar update
CEO Peter Ekolind was scheduled to discuss recent strategic decisions concerning CG01, the focus on gene therapy, and the introduction of a cost-reduction program.
Webinar arranged by Västra Hamnen Corporate Finance was scheduled for 15:00 CET on 31 October 2024; recording to be published afterward on Västra Hamnen’s YouTube channel.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Lärkberget
- Profitability returned in H1 2026, but NAV fell as NAXS shares declined in value.LARK
H1 2026 - Shifted to investment focus, posted positive H2, and grew NAV per share to 3.08 SEK.LARKQ4 2025
- Strategic shift to investment focus completed; strong cash, first investments imminent.LARKQ2 2025
- Strategic Partner A/S proposes a new board led by Luca Di Stefano for CombiGene.LARKInvestor Update
- Gene therapy focus sharpened, COZY prioritized, and cost cuts extend liquidity to 2026.LARKQ3 2024
- CG01 rights regained, CGT2 discontinued, COZY advanced; sales and cash declined year-over-year.LARKQ2 2024
- CombiGene halts R&D, posts SEK 44.9m loss, and shifts focus to investments or dividends.LARKQ4 2024